References
- Jellinger KA. Neuropathology of Parkinson’s’ disease. In: Thomas M, editor. Inflammation in Parkinson’s Disease: Scientific and Clinical Aspects. Springer; NY, USA: 2014. p. 25-47
- Gallegos S, Pacheco C, Peters C, et al. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease. Front Neurosci 2015;9:59
- Hernandez DG, Singleton AB. Genetics of Parkinson’s disease. In: Brás JMT, editor. Movement disorder genetics Schneider. Springer; SA: 2015. p. 19-34
- Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron 2015;85:257-73
- Gardner RC, Burke JF, Nettiksimmons J, et al. Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol 2015;77:987-95
- Bu XL, Wang X, Xiang Y, et al. The association between infectious burden and Parkinson’s disease: A case-control study. Parkinsonism Relat Disord 2015;21:877-81
- Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 2015;31:140-9
- Rodriguez M, Rodriguez-Sabate C, Morales I, et al. Parkinson’s disease as a result of aging. Aging Cell 2015;14:293-308
- Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 2015;9:124
- Goldman SM. Environmental toxins and Parkinson’s disease. Annu Rev Pharmacol Toxicol 2014;54:141-64
- Eschbach J, Danzer KM. alpha-Synuclein in Parkinson’s disease: pathogenic function and translation into animal models. Neurodegener Dis 2014;14:1-17
- Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 2015;46:101-16
- Jellinger KA. Synuclein and parkinson’s disease: an update. In: Martinez A, Gil C, editors. Emerging drugs and targets for parkinson’s disease. The Royal Society of; Chemistry; London, UK: 2013. p. 175-214
- Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain. Brain 2015;138:1642-57
- Riley BE, Gardai SJ, Emig-Agius D, et al. Systems-based analyses of brain regions functionally impacted in Parkinson’s disease reveals underlying causal mechanisms. PLoS One 2014;9(8):e102909
- Hurley MJ, Brandon B, Gentleman SM, Dexter DT. Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 2013;136:2077-97
- Schulz-Schaeffer WJ. Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s disease? Biomolecules 2015;5:1467-79
- Kovacs GG, Breydo L, Green R, et al. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis 2014;69:76-92
- Peelaerts W, Bousset L, Van der Perren A, et al. Alpha-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015;522:340-4
- Schweighauser M, Bacioglu M, Fritschi SK, et al. Formaldehyde-fixed brain tissue from spontaneously ill alpha-synuclein transgenic mice induces fatal alpha-synucleinopathy in transgenic hosts. Acta Neuropathol 2015;129:157-9